OTUD5 Regulates p53 Stability by Deubiquitinating p53

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Luo, Judong ^a,b   Lu, Zhonghua ^a   Lu, Xujing ^a   Chen, Ling ^a   Cao, Jianping ^b   Zhang, Shuyu ^b   Ling, Yang ^a   Zhou, Xifa ^a  

^a SOOCHOW UNIVERSITY   (China)

^b MEDICAL COLLEGE OF SOOCHOW UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

OTUD5 PROTEIN; PROTEIN P53; REGULATOR PROTEIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; DEUBIQUITINATION; DNA DAMAGE; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; UBIQUITINATION;

APOPTOSIS; CELL LINE; DNA DAMAGE; ENDOPEPTIDASES; HUMANS; PROTEIN STABILITY; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITIN-SPECIFIC PROTEASES; UBIQUITINATION;

EID: 84885452884     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0077682     Document Type: Article

References (27)

1. Horn HF, Vousden KH, (2007) Coping with stress: multiple ways to activate p53. Oncogene 26: 1306-1316. doi:10.1038/sj.onc.1210263. PubMed: 17322916.
2. Vousden KH, Lane DP, (2007) p53 in health and disease. Nat Rev Mol Cell Biol 8: 275-283. doi:10.1038/nrm2147. PubMed: 17380161.
3. Kruse JP, Gu W, (2009) Modes of p53 regulation. Cell 137: 609-622. doi:10.1016/j.cell.2009.04.050. PubMed: 19450511.
4. Li T, Kon N, Jiang L, Tan M, Ludwig T, et al. (2012) Tumor suppression in the absence of p53-mediated cell-cycle arrest, apoptosis, and senescence. Cell 149: 1269-1283. doi:10.1016/j.cell.2012.04.026. PubMed: 22682249.
5. Nijman SM, Luna-Vargas MP, Velds A, Brummelkamp TR, Dirac AM, et al. (2005) A genomic and functional inventory of deubiquitinating enzymes. Cell 123: 773-786. doi:10.1016/j.cell.2005.11.007. PubMed: 16325574.
6. Komander D, Clague MJ, Urbé S, (2009) Breaking the chains: structure and function of the deubiquitinases. Nat Rev Mol Cell Biol 10: 550-563. doi:10.1038/nrm2731. PubMed: 19626045.
7. Li M, Brooks CL, Kon N, Gu W, (2004) A dynamic role of HAUSP in the p53-Mdm2 pathway. Mol Cell 13: 879-886. doi:10.1016/S1097-2765(04)00157-1. PubMed: 15053880.
8. Cummins JM, Vogelstein B, (2004) HAUSP is required for p53 destabilization. Cell Cycle 3: 689-692. PubMed: 15118411.
9. Li M, Chen D, Shiloh A, Luo J, Nikolaev AY, et al. (2002) Deubiquitination of p53 by HAUSP is an important pathway for p53 stabilization. Nature 416: 648-653. doi:10.1038/nature737. PubMed: 11923872.
10. Meulmeester E, Maurice MM, Boutell C, Teunisse AF, Ovaa H, et al. (2005) Loss of HAUSP-mediated deubiquitination contributes to DNA damage-induced destabilization of Hdmx and Hdm2. Mol Cell 18: 565-576. doi:10.1016/j.molcel.2005.04.024. PubMed: 15916963.
11. Yuan J, Luo K, Zhang L, Cheville JC, Lou Z, (2010) USP10 regulates p53 localization and stability by deubiquitinating p53. Cell 140: 384-396. doi:10.1016/j.cell.2009.12.032. PubMed: 20096447.
12. Liu J, Chung HJ, Vogt M, Jin Y, Malide D, et al. (2011) JTV1 co-activates FBP to induce USP29 transcription and stabilize p53 in response to oxidative stress. EMBO J 30: 846-858. doi:10.1038/emboj.2011.11. PubMed: 21285945.
13. Stevenson LF, Sparks A, Allende-Vega N, Xirodimas DP, Lane DP, et al. (2007) The deubiquitinating enzyme USP2a regulates the p53 pathway by targeting Mdm2. EMBO J 26: 976-986. doi:10.1038/sj.emboj.7601567. PubMed: 17290220.
14. Hock AK, Vigneron AM, Carter S, Ludwig RL, Vousden KH, (2011) Regulation of p53 stability and function by the deubiquitinating enzyme USP42. EMBO J 30: 4921-4930. doi:10.1038/emboj.2011.419. PubMed: 22085928.
15. Kayagaki N, Phung Q, Chan S, Chaudhari R, Quan C, et al. (2007) DUBA: a deubiquitinase that regulates type I interferon production. Science 318: 1628-1632. doi:10.1126/science.1145918. PubMed: 17991829.
16. Sowa ME, Bennett EJ, Gygi SP, Harper JW, (2009) Defining the human deubiquitinating enzyme interaction landscape. Cell 138: 389-403. doi:10.1016/j.cell.2009.04.042. PubMed: 19615732.
17. Miao L, Song Z, Jin L, Zhu YM, Wen LP, et al. (2010) ARF antagonizes the ability of Miz-1 to inhibit p53-mediated transactivation. Oncogene 29: 711-722. doi:10.1038/onc.2009.372. PubMed: 19901969.
18. Cox RF, (1984) Managing skin damage induced by doxorubicin hydrochloride and daunorubicin hydrochloride. Am J Hosp Pharm. 41(11):: 2410-2414. PubMed: 6150636.
19. Dai C, Gu W, (2010) p53 post-translational modification: deregulated in tumorigenesis. Trends Mol Med 16: 528-536. doi:10.1016/j.molmed.2010.09.002. PubMed: 20932800.
20. Grossman SR, Deato ME, Brignone C, Chan HM, Kung AL, et al. (2003) Polyubiquitination of p53 by a ubiquitin ligase activity of p300. Science 300: 342-344. doi:10.1126/science.1080386. PubMed: 12690203.
21. Haupt Y, Maya R, Kazaz A, Oren M, (1997) Mdm2 promotes the rapid degradation of p53. Nature 387: 296-299. doi:10.1038/387296a0. PubMed: 9153395.
22. Kubbutat MH, Jones SN, Vousden KH, (1997) Regulation of p53 stability by Mdm2. Nature 387: 299-303. doi:10.1038/387299a0. PubMed: 9153396.
23. Münger K, Howley PM, (2002) Human papillomavirus immortalization and transformation functions. Virus Res 89: 213-228. doi:10.1016/S0168-1702(02)00190-9. PubMed: 12445661.
24. Shi D, Pop MS, Kulikov R, Love IM, Kung AL, et al. (2009) CBP and p300 are cytoplasmic E4 polyubiquitin ligases for p53. Proc Natl Acad Sci U S A 106: 16275-16280. doi:10.1073/pnas.0904305106. PubMed: 19805293.
25. Chen D, Kon N, Li M, Zhang W, Qin J, et al. (2005) ARF-BP1/Mule is a critical mediator of the ARF tumor suppressor. Cell 121: 1071-1083. doi:10.1016/j.cell.2005.03.037. PubMed: 15989956.
26. Brooks CL, Gu W, (2006) p53 ubiquitination: Mdm2 and beyond. Mol Cell 21: 307-315. doi:10.1016/j.molcel.2006.01.020. PubMed: 16455486.
27. Uldrijan S, Pannekoek WJ, Vousden KH, (2007) An essential function of the extreme C-terminus of MDM2 can be provided by MDMX. EMBO J 26: 102-112. doi:10.1038/sj.emboj.7601469. PubMed: 17159902.